Your browser doesn't support javascript.
loading
Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital.
Karer, Matthias; Haider, Teresa; Kussmann, Manuel; Obermüller, Markus; Tiehen, Claas; Burgmann, Heinz; Lagler, Heimo; Traby, Ludwig.
Afiliación
  • Karer M; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Department of Clinical Pharmacology, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Haider T; Department of Neurophysiology, Center for Brain Research, Medical University Vienna, Spitalgasse 4, 1090 Vienna, Austria.
  • Kussmann M; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Obermüller M; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Tiehen C; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Burgmann H; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Lagler H; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: heimo.lagler@meduniwien.ac.at.
  • Traby L; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Int J Antimicrob Agents ; 59(1): 106481, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34801678
ABSTRACT

OBJECTIVES:

Due to recent safety concerns regarding fluoroquinolones and the potential medical and economic benefits, we investigated the efficacy of a single intravenous dose of 1.5 g azithromycin for the treatment of pulmonary legionellosis.

METHODS:

Using a nationwide legionellosis registry for pre-selection, 74 patients admitted from 2000-2018 to a tertiary care hospital owing to pneumonia caused by Legionella pneumophila were retrospectively included in this study.

RESULTS:

Conventional treatment regimens consisting of fluoroquinolones (n = 20), macrolides (n = 30) or combinations of both (n = 24) and a single intravenous dose of azithromycin (n = 12) have been demonstrated to be equally effective. Single-dose azithromycin treatment was well tolerated and resulted in a shorter hospital stay (P = 0.0464) and shorter antibiotic treatment duration (P = 0.0004) allowing earlier discharge.

CONCLUSION:

A single intravenous dose of azithromycin might be a valuable treatment alternative for patients with legionellosis.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Legionelosis / Azitromicina / Fluoroquinolonas / Centros de Atención Terciaria / Antibacterianos Tipo de estudio: Observational_studies País/Región como asunto: Europa Idioma: En Revista: Int J Antimicrob Agents Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Legionelosis / Azitromicina / Fluoroquinolonas / Centros de Atención Terciaria / Antibacterianos Tipo de estudio: Observational_studies País/Región como asunto: Europa Idioma: En Revista: Int J Antimicrob Agents Año: 2022 Tipo del documento: Article